NEW YORK, NY / ACCESSWIRE / October 16, 2017 / Shares of Celgene Corporation saw a small gain on Friday despite any news, while Valeant Pharmaceuticals saw a loss of roughly 3% despite not having any significant news either. Valeant recently celebrated its Ortho Dermatologics division's impressive results from its AMAGINE-2 trial demonstrating the Siliq injection.

RDI Initiates Coverage on:

Celgene Corporation
https://rdinvesting.com/news/?ticker=CELG

Valeant Pharmaceuticals International, Inc.
https://rdinvesting.com/news/?ticker=VRX

Celgene Corporation shares closed down 1.47% on Friday with a little over 5 million shares traded. There was no remarkable news from the company but earlier in the month, it was announced that Nimbus Therapeutics and Celgene have initiated a long-term strategic alliance in immunology. In the alliance, Celgene will receive an option to acquire each program in the alliance up through a clinical inflection point. For each program the company chooses to acquire, Nimbus will receive a payment upfront and then potential milestone payments downstream. Celgene Executive Vice President and President of Global Research and Early Development, Rupert Vessey, F.r.C.P., D.Phil, commented, "Celgene is committed to the continued growth of our expanding immunology and inflammation pipeline, and believes that the Nimbus immunology programs, including their efforts on Tyk2 and STING antagonists, represent important additions as we work to create the next generation of drug candidates for patients with autoimmune disorders." Recently, Vetr upgraded its rating on Celgene shares from "hold" to buy" and gave it a $146.58 price target on October 6th.

Access RDI's Celgene Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CELG

Valeant Pharmaceuticals International, Inc. shares closed down 3.18% this past Friday on nearly 16 million shares traded. The pharma company's Ortho Dermatologics division announced results recently from the long-term phase III extension study of AMAGINE-2 that demonstrated that Siliq injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis. Siliq is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients. The patients are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Valeant CEO Joseph C. Papa commented, "I am pleased to see the durable efficacy of SILIQ demonstrated through these additional findings. This dermatologic innovation has been shown to not only provide relief for many patients who suffer from moderate-to-severe plaque psoriasis, but also had an overall positive impact on the quality of life of these patients." Lawrence J. Green, M.D. the associate clinical professor of Dermatology at George Washington University School of Medicine remarked, "More than 65 percent of both ustekinumab-naïve and -experienced patients in AMAGINE-1 receiving SILIQ treatment experienced complete clearance (PASI 100) at week 52, making this an excellent solution with proven results for a wide range of patients with moderate-to-severe psoriasis."

Access RDI's Valeant Pharmaceuticals International, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX

Our Actionable Research on Celgene Corporation (NASDAQ: CELG) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com